Abstract:Diclofenac (DCF) is well-known non-steroidal anti-inflammatory drug used in the treatment of several cancer cell lines. DCF is derived from phenylacetic acid, and its pharmaceutical activity is attributed to the carboxylic acid moiety. The carboxylic acid group is also responsible for the DCF's side effects, which include gastrointestinal bleeding and ulceration. Therefore, researchers do vast efforts and proposed many strategies to reduce DCF hepatotoxicity. In this regard, the present review provides a comparison and insight into recent developments in DCF through structural modification, drug delivery carriers (multiparticles, microparticles, and nanoparticles), and pharmacokinetics to reduce the toxicity side effects while simultaneously enhancing sustained drug release and the pharmaceutical effect. The researchers demonstrated that the nature and quantity of polymeric drug vehicles (hydrophilic or hydrophobic polymers) have a profound effect on DCF release rate, encapsulation efficiency, and mechanism of action. Furthermore, masking the DCF carboxylic acid with certain moieties such as hydrazones or heterocyclics could substantially boost the pharmaceutical and anticancer activities with a significant reduction in ulcerogenic effect. In this review, comparisons between the published DCF prodrugs, commercial formulations, and parent drug DCF based on the pharmacokinetics (the area under the concentration-time curve from dosing time 0 to ∞, time to reach the maximum concentration, and concentration of the agent inhibiting cell growth by 50%) were also elucidated. It also briefly summarizes the synergistic interactions between DCF with some bio-enhancers. In the last section, we highlighted how the researchers incorporated artificial intelligence during the drug formulation to overcome hepatotoxicity and used it to predict its activity against cancer cell lines. In the last line, this review will serve as compilation of useful and recent sources, which are indexed in Scopus, PubMed, Academic Search Complete, and others, on how scientists created more efficient and sustained release DCF formulations, and how they made it safer with almost no side effects. Graphical abstract Download : Download high-res image (200KB) Download : Download full-size image

Re-design and evaluation of diclofenac-based carborane-substituted prodrugs and their anti-cancer potential

Carborane Conjugates with Ibuprofen, Fenoprofen and Flurbiprofen: Synthesis, Characterization, COX Inhibition Potential and In Vitro Activity

Design, Synthesis, and Biological Evaluation of Novel Urea-Containing Carnosic Acid Derivatives with Anticancer Activity

Biological Evaluation and Molecular Docking Studies of Novel 1,3,4-Oxadiazole Derivatives of 4,6-Dimethyl-2-sulfanylpyridine-3-carboxamide

The More the Better-Investigation of Polymethoxylated N-Carboranyl Quinazolines as Novel Hybrid Breast Cancer Resistance Protein Inhibitors

Carboranes as Potent Phenyl Mimetics: A Comparative Study on the Reversal of ABCG2-Mediated Drug Resistance by Carboranylquinazolines and Their Organic Isosteres

Structure-Activity Relationship Study of New Carbazole Sulfonamide Derivatives as Anticancer Agents with Dual-target Mechanism

Design, synthesis and anticancer activity studies of 3-(coumarin-3-yl)-acrolein derivatives: Evidenced by integrating network pharmacology and vitro assay

Diclofenac derivatives as promising anticancer and anti-inflammatory drug: Synthesis, formulations, and pharmacokinetics

Design, Synthesis, and Evaluation of Novel Coumarin-Dithiocarbamate Derivatives (ids) As Anti-Colorectal Cancer Agents

Rational Design, Synthesis, Molecular Docking, and Biological Evaluations of New Phenylpiperazine Derivatives of 1,2-Benzothiazine as Potential Anticancer Agents

Design, synthesis and mechanism of action of novel 1,9-disubstituted beta-carboline derivatives as antitumor agents

Rational design of ibuprofen-based redox-responsive anti-cancer polymeric drug delivery systems

Design, synthesis and cytotoxic evaluation of novel betulonic acid-diazine derivatives as potential antitumor agents

Design, synthesis, and ex vivo anti-drug resistant cervical cancer activity of novel molecularly targeted chalcone derivatives

New Oxazolo[5,4- d]pyrimidines as Potential Anticancer Agents: Their Design, Synthesis, and In Vitro Biological Activity Research

Discovery of Novel Heteroarylmethylcarbamodithioates As Potent Anticancer Agents: Synthesis, Structure-Activity Relationship Analysis and Biological Evaluation.

Evaluation of doxorubicin and β-lapachone analogs as anticancer agents, a biological and computational study

Design, synthesis, molecular modeling and evaluation of 2,4-diaminopyrimidine analogues as promising colorectal cancer drugs

Novel carboranyl-BODIPY conjugates: design, synthesis and anti-cancer activity

Synthesis, DFT, ADMET, and Docking studies of Novel Sulfonyl Piperidine Analogues containing 2,3-Dihydrobenzofuran-5-Carboxamide